References
- Friedmann P., Garb J. L., Park W. C., et al. Survival following moderate-dose preoperative radiation therapy for carcinoma of the rectum. Cancer 1985; 55: 967–973
- Kodner I. J., Shemesh E., Fry R. D., et al. Preoperative irradiation for rectal cancer. Ann Surg. 1989; 209: 194–199
- Coates A., Abraham S., Kaye S. B., et al. On the receiving end; patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19: 203–208
- Asklen L. A., Karwinski B., Maartmann-Moe H., et al. Periodicity in metastatic tumor growth demonstrated in the human liver at autopsy. Invasion Metastasis 1991; 11: 58–64
- Davis H. L. Chemotherapy of large bowel cancer. Cancer (Phila.) 1982; 50: 2638–2646
- Erlichmann C., Fine S., Wong A., et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988; 6: 469–475
- Arbuck S. C. Overview of clinical trial using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer (Phila) 1989; 63: 1036–1044
- O'Connell M. J. A phase 3 trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer (Phila) 1989; 63: 1026–1030
- Coates A., Glasziou P., McNeil D. On the receiving end, 111: measurement of quality of life during cancer chemotherapy. Annul Oncology 1990; 1: 213–217
- Coates A., Dillenbeck F., McNeil D. R., et al. On the receiving end, II: linear analogue self assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol. 1983; 19: 1633–1637
- Tsukagoshi S., Hashimoto Y., Fujii G., et al. Krestin (PSK). Cancer Treatment Reviews 1984; 11: 131–155
- Windle R., Bell P. RF, Shaw D. Five year result of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg. 1987; 74: 569–572
- Moertel C. G., Fleming T. R., Macdonald J. S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322: 352–358
- Tsuru S., Shinomiya N. Effect of PSK on the defense mechanisms in tumor-bearing hosts. Biotherapy 1990; 4: 907–914
- Shibata Y., Tamura K., Ishida N. In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of a l-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Rex 1983; 43: 2889–2896
- Toge T. Immunosuppressive mechanisms in cancer patients and antagonistic activity of PSK. Biotherapy 1990; 4: 899–906
- Matsunaga K., Tsuru S., Morita I., et al. Competitive effect of PSK against immunosuppressive factor obtained from tumor-bearing mice. Jpn J Cancer Chemother. 1980; 7: 496–503